See more : Zeuus, Inc. (ZUUS) Income Statement Analysis – Financial Results
Complete financial analysis of Chinook Therapeutics, Inc. (KDNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chinook Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Samyang Holdings Corporation (000075.KS) Income Statement Analysis – Financial Results
- NiSource Inc. (NI) Income Statement Analysis – Financial Results
- Shibaura Electronics Co.,Ltd. (6957.T) Income Statement Analysis – Financial Results
- Summit Industrial Income REIT (SMMCF) Income Statement Analysis – Financial Results
- Tailam Tech Construction Holdings Limited (6193.HK) Income Statement Analysis – Financial Results
Chinook Therapeutics, Inc. (KDNY)
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.13M | 51.63M | 827.00K | 17.26M | 15.09M | 17.24M | 50.68M | 72.98M |
| Cost of Revenue | 1.72M | 1.69M | 422.00K | 554.00K | 584.00K | 559.00K | 549.00K | 89.00K |
| Gross Profit | 4.41M | 49.94M | 405.00K | 16.70M | 14.50M | 16.68M | 50.13M | 72.89M |
| Gross Profit Ratio | 71.90% | 96.73% | 48.97% | 96.79% | 96.13% | 96.76% | 98.92% | 99.88% |
| Research & Development | 141.21M | 96.99M | 36.05M | 17.01M | 75.84M | 89.38M | 87.72M | 58.65M |
| General & Administrative | 36.29M | 31.90M | 19.07M | 2.96M | 36.04M | 33.75M | 34.28M | 27.81M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 36.29M | 31.90M | 19.07M | 2.96M | 36.04M | 33.75M | 34.28M | 27.81M |
| Other Expenses | 1.72M | 1.69M | 422.00K | 299.00K | 3.99M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 179.22M | 130.57M | 55.54M | 19.97M | 115.86M | 123.13M | 122.00M | 86.45M |
| Cost & Expenses | 179.22M | 130.57M | 55.54M | 19.97M | 116.45M | 123.69M | 122.54M | 86.54M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 7.18M | 0.00 | 15.00K | 33.00K | 0.00 | 0.00 | 2.22M | 494.00K |
| Depreciation & Amortization | 20.89M | 41.87M | 2.25M | 520.00K | 4.95M | 3.99M | 2.55M | 0.00 |
| EBITDA | -164.20M | -57.17M | -53.98M | -19.45M | -101.36M | -106.45M | -71.86M | -13.56M |
| EBITDA Ratio | -2,679.44% | -110.74% | -6,527.45% | -112.68% | -671.84% | -617.51% | -141.79% | -18.59% |
| Operating Income | -185.08M | -99.04M | -56.23M | -19.97M | -101.36M | -106.45M | -71.86M | -13.56M |
| Operating Income Ratio | -3,020.28% | -191.84% | -6,798.91% | -115.69% | -671.84% | -617.51% | -141.79% | -18.59% |
| Total Other Income/Expenses | 4.81M | -170.00K | -27.40M | -64.82M | 5.22M | 3.23M | 2.18M | -25.74M |
| Income Before Tax | -180.27M | -99.21M | -83.63M | -46.52M | -96.14M | -103.23M | -69.68M | -39.31M |
| Income Before Tax Ratio | -2,941.81% | -192.17% | -10,111.85% | -269.55% | -637.24% | -598.80% | -137.50% | -53.86% |
| Income Tax Expense | 4.34M | 2.09M | -2.00M | 332.00K | 783.00K | 11.36M | -21.46M | -99.00K |
| Net Income | -184.62M | -101.30M | -81.62M | -46.85M | -95.36M | -91.86M | -91.15M | -39.21M |
| Net Income Ratio | -3,012.65% | -196.22% | -9,869.65% | -271.47% | -632.05% | -532.88% | -179.85% | -53.73% |
| EPS | -2.87 | -2.22 | -6.20 | -1.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.87 | -2.22 | -6.20 | -1.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 64.37M | 45.61M | 13.17M | 42.16M | 78.81B | 72.90B | 65.20B | 44.71B |
| Weighted Avg Shares Out (Dil) | 64.37M | 45.61M | 13.17M | 42.16M | 78.81B | 72.90B | 65.20B | 44.71B |
7 Cheap Biotech Stocks to Buy Now
Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.
Chinook Therapeutics to Present at Upcoming Investor Conferences
SEATTLE, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in the following...
Here's Why "Trend" Investors Would Love Betting on Chinook (KDNY)
Chinook (KDNY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Chinook (KDNY) Stock Rallies 24.2% in 3 Months: Here's Why
Despite no marketable drugs in its portfolio, Chinook (KDNY) is progressing well with its pipeline. Updated data from a study supports the potential clinical utility of BION-1301 in the IgA nephropathy indication.
Checking Out Chinook Therapeutics
Shares of Chinook Therapeutics have reacted well recently to a surprising secondary offering conducted at $14.00, providing it with additional capital for the commercialization of atrasentan. Although only one (likely) inferior therapy has been approved for the company's initial target...
4 Small Stocks to Bet on in an Upbeat Drugs Industry
It is expected that innovation will continue to drive growth in the Medical-Drugs industry in 2022. KDNY, ASRT, VIRX, SLNO may prove to be good additions to one's portfolio.
Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2022
SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a fireside...
Chinook Therapeutics Receives Orphan Drug Designation from European Commission for BION-1301 for Treatment of Primary IgA Nephropathy (IgAN)
SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the European Commission has granted orphan drug designation for BION-1301...
Here's Why Momentum in Chinook (KDNY) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Chinook (KDNY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Wall Street Analysts See a 94% Upside in Chinook (KDNY): Can the Stock Really Move This High?
The consensus price target hints at a 93.8% upside potential for Chinook (KDNY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside...
Source: https://incomestatements.info
Category: Stock Reports